Innate Pharma S.A. (EPA:IPH)
France
· Delayed Price · Currency is EUR | Market Cap | 154.84M |
| Revenue (ttm) | 12.64M |
| Net Income (ttm) | -46.05M |
| Shares Out | 92.17M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | 9.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,843 |
| Average Volume | 337,828 |
| Open | 1.700 |
| Previous Close | 1.680 |
| Day's Range | 1.670 - 1.760 |
| 52-Week Range | 1.330 - 2.500 |
| Beta | 0.51 |
| RSI | 49.06 |
| Earnings Date | Nov 12, 2025 |
About Innate Pharma
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ... [Read more]
Financial Performance
In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.
Financial StatementsNews
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of November 27, 2025.
Innate Pharma to Present at Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Congress--Innate Pharma to present at Jefferies Global Healthcare Conference.
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Innate Pharma (IPHA) Reports Significant Revenue Decline in 9M 2025
Innate Pharma (IPHA) Reports Significant Revenue Decline in 9M 2025
Innate Pharma reports 9M results
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial...
Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacutamab Trial
Innate Pharma (IPHA) Gains FDA Approval to Advance Phase 3 Lacutamab Trial
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Admin...
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the Company will hold a conf...
Innate Pharma (IPHA) Upgraded to Buy by HC Wainwright & Co. | IPHA Stock News
Innate Pharma (IPHA) Upgraded to Buy by HC Wainwright & Co. | IPHA Stock News
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
BTIG Reiterates Buy Rating for Innate Pharma (IPHA) with $8 Target | IPHA Stock News
BTIG Reiterates Buy Rating for Innate Pharma (IPHA) with $8 Target | IPHA Stock News
Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript
Innate Pharma S.A. (NASDAQ:IPHA) Analyst/Investor Day October 28, 2025 8:00 AM EDT Company Participants Jonathan Dickinson - CEO & Director Sonia Quaratino - Executive VP & Chief Medical Officer Stép...
Innate Pharma S.A. (IPHA) Analyst/Investor Day - Slideshow
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an analyst and ...
This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
IPHA: Leerink Partners Downgrades Innate Pharma, Lowers Price Target | IPHA Stock News
IPHA: Leerink Partners Downgrades Innate Pharma, Lowers Price Target | IPHA Stock News
Innate Pharma (IPHA) Downgrade: What Investors Need to Know | IPHA Stock News
Innate Pharma (IPHA) Downgrade: What Investors Need to Know | IPHA Stock News
Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial ...
Innate Pharma SA (IPHA) (H1 2025) Earnings Call Highlights: Strategic Focus and Financial Resilience Amidst Challenges
Half Year 2025 Innate Pharma SA Earnings Call Transcript
Half Year 2025 Innate Pharma SA Earnings Call Transcript
Innate Pharma S.A. GAAP EPS of -€0.25, revenue of €4.9M
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
Discover Innate Pharma’s H1 2025 results, strategic pipeline focus, and updates on key
Innate Pharma S.A. 2025 Q2 - Results - Earnings Call Presentation
2025-09-17. The following slide deck was published by Innate Pharma S.A.
Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops
(RTTNews) - Innate Pharma S.A. (IPHA, IPH.PA), a French biotechnology firm, on Wednesday reported a narrower first-half net loss mainly aided by reduced expenses, amid weak revenues.
Earnings Scheduled For September 17, 2025
Companies Reporting Before The Bell • 111 (NASDAQ: YI) is likely to report earnings for its second quarter. • Innate Pharma (NASDAQ: IPHA) is likely to report earnings for its first quarter. • Gener...